Puma Biotechnology, Inc. - News Releases

Get News Alerts by RSS

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

12/16/2019

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

12/13/2019

Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS

12/12/2019

plasmaMATCH Trial Shows Neratinib Activity in ERBB2 (HER2) Mutant Metastatic Breast Cancer

12/11/2019

Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium

12/02/2019

Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Singapore for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer

12/02/2019

Puma Biotechnology Amends License Agreement with Pierre Fabre to Include Additional Countries

11/06/2019

Puma Biotechnology Reports Third Quarter 2019 Financial Results

11/05/2019

Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Registration Approval in Hong Kong for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer

11/04/2019

Puma Biotechnology to Present at the Credit Suisse Healthcare Conference

10/23/2019

Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

10/03/2019

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

10/02/2019

FDA Approves Labeling Supplement for Puma Biotechnology’s NERLYNX® (neratinib) for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

09/25/2019

Puma Biotechnology to Present at Cantor Global Healthcare Conference

09/11/2019

Puma Biotechnology Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer

09/05/2019

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

09/04/2019

Puma Biotechnology Licensing Partner Pint Pharma Receives Marketing Authorization for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive, HER2-Positive Breast Cancer

09/03/2019

Puma Biotechnology to Present at the H.C. Wainwright 21st Annual Global Investment Conference

09/03/2019

FDA Grants Orphan Drug Designation to Puma Biotechnology’s NERLYNX® for the Treatment of Breast Cancer Patients with Brain Metastases

08/08/2019

Puma Biotechnology Reports Second Quarter 2019 Financial Results

08/06/2019

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

07/25/2019

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

07/24/2019

Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results

07/16/2019

Puma Biotechnology’s Licensing Partner Knight Therapeutics Receives Regulatory Approval from Health Canada to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of Hormone Receptor Positive, HER2-Positive Early Stage Breast Cancer

07/03/2019

Puma Biotechnology Presents Interim Results from the Biliary Tract Cohort of its Phase II SUMMIT Basket Trial of Neratinib at the ESMO World Congress on Gastrointestinal Cancer 2019

07/01/2019

Puma Biotechnology Submits a Supplemental New Drug Application to U.S. FDA for Neratinib to Treat HER2-Positive Metastatic Breast Cancer

06/05/2019

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

06/04/2019

Puma Biotechnology Presents Results from Phase III NALA Trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer at the ASCO 2019 Annual Meeting

06/02/2019

Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the ASCO 2019 Annual Meeting

05/29/2019

Puma Biotechnology to Present at Jefferies 2019 Global Healthcare Conference

05/09/2019

Puma Biotechnology Reports First Quarter 2019 Financial Results

05/08/2019

Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2019

05/03/2019

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

04/25/2019

Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results

04/09/2019

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

04/04/2019

Puma Biotechnology Expands Cohorts in Phase II SUMMIT Trial of Neratinib in Cancer Patients with Tumors with Activating EGFR or HER2 Mutations

04/01/2019

Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe

03/28/2019

Puma Biotechnology Announces Publication of Abstracts on Neratinib for AACR Annual Meeting 2019

03/18/2019

Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for HER2 (ERBB2) Mutant, Metastatic Cervical Cancer at the Society of Gynecologic Oncology (SGO) 2019 Annual Meeting

03/18/2019

Puma Biotechnology’s Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

03/14/2019

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

03/05/2019

Puma Biotechnology to Present at Cowen’s Annual Health Care Conference

02/28/2019

Puma Biotechnology Reports Fourth Quarter and Full Year 2018 Financial Results

02/15/2019

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

02/13/2019

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results

02/04/2019

Puma Biotechnology Announces Litigation Victory with Jury’s Decision

01/11/2019

Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX® (neratinib) in Canada

01/03/2019

Puma Biotechnology to Present at J. P. Morgan Healthcare Conference

01/02/2019

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)